Competitive signals are early clues hiding in plain sight across public data, such as clinical trial updates, patent filings, regulatory activity and licensing deals, that show where a competitor may be heading before the market fully reacts. In pharma, the real insight comes from connecting those signals, because a single filing or trial change means less than the pattern they form over time.
Every year, pharmaceutical business development and R&D teams make decisions worth hundreds of millions of dollars based on an incomplete picture of the competitive landscape. GSK’s 2025 agreement with Hengrui Pharma – $500 million upfront, with total milestone-based value that could reach $12.5 billion – illustrates the scale of these bets (GSK, 2025). The competitive signals informing such decisions were almost always available in advance. They were not hidden in proprietary databases or buried in confidential filings. They were sitting in clinical trial registries, patent offices, regulatory dockets and deal disclosures, just waiting to be connected.
The difference between organizations that catch those signals and those that miss them is not access. It is synthesis.
What a competitive signal actually looks like
A true competitive signal is not a press release. It is a pattern – a sequence of observable events that read together, reveals intent before it becomes a public fact. Four signal types carry the greatest strategic consequence in biopharma (DrugPatentWatch, 2025):
- Competitor pipeline activity: which compounds rivals are advancing, clinical phase, target indications and mechanism of action
- Patent activity: IP barriers to market entry, claim structures that must be designed around, challenged, or licensed
- Regulatory activity: FDA and EMA guidance, advisory committee decisions, approval actions and enforcement activity
- Deal and licensing activity: Deal timing, structure and valuation
Each domain generates public data. The signal is not in any single data point – it is in the convergence.
The four primary competitive signal types in pharma
Signal type 1: Competitor pipeline activity
The foundation of biopharma competitive intelligence is pipeline activity, but many organizations monitor it too late in the development cycle. Teams tracking only Phase 3 trials are observing competitors long after key strategic decisions are locked in. Leading organizations instead look for early-phase competitive intelligence signals. They monitor Phase 1 registrations, investigational new drug filings and conference abstracts that appear before formal registry updates. By the time a compound reaches late-stage trials, its indication, mechanism and patient population are set. Early phase surveillance helps teams see where resources are concentrating, allowing them to differentiate their assets or avoid crowded therapeutic areas.
Pipeline clustering by indication provides highly actionable intelligence for portfolio strategy. When multiple sponsors advance similar mechanisms in the same indication, the pattern becomes clear well before any individual trial results are published. For business development (BD) directors, this directly impacts asset valuation. A compound entering a field with three Phase 2 competitors carries a very different commercial profile than one in an empty field. For R&D leaders, this data shapes trial design. Endpoint selection, patient targeting and comparator arms must account for what competitors are testing. If several Phase 3 trials adopt the same primary endpoint, that metric becomes the regulatory expectation.
Signal type 2: Patent activity
Patent filings are among the earliest indicators of competitive intent in the life sciences sector. However, many pharma competitive intelligence teams overlook them by treating intellectual property strictly as a legal matter rather than a strategic signal. Patent applications in most jurisdictions publish 18 months after their priority date. This means the filing reveals R&D decisions made nearly two years prior. A competitor’s patent footprint, when analyzed alongside their clinical pipeline, shows where they are building commercial exclusivity and which biological targets they consider proprietary. When a company files patents around a specific target alongside an IND filing, the combined signals confirm a clear strategic commitment.
The value of patent landscape analysis goes beyond monitoring what competitors own. It also highlights what they do not own. White space analysis maps validated biological targets, patient subpopulations and therapeutic mechanisms that remain legally uncrowded. These gaps offer first-mover IP opportunities for organizations actively monitoring the landscape. Additionally, tracking the cadence of patent filings relative to clinical trial initiation is critical. Trial registrations can serve as prior art, potentially invalidating patent claims filed after a protocol becomes public. Integrating patent and clinical trial data provides teams with a comprehensive view of both opportunities and exposures.
Signal type 3: Regulatory activity
Regulatory events provide valuable signals of competitive intelligence, yet many teams treat them merely as news updates rather than as structural insights. When a sponsor submits a Pediatric Study Plan or receives a Special Protocol Assessment, the timing reflects their regulatory risk tolerance and development timeline. A competitor filing for Fast Track Designation or Accelerated Approval indicates confidence in the unmet need and in available surrogate endpoints. Each of these regulatory milestones impacts the broader competitive landscape and helps competing teams adjust their own launch sequencing.
Specific agency actions offer highly predictive insights for the broader market. When the FDA or EMA publishes new guidance, it reveals their evolving expectations for clinical endpoints, trial design and safety data across an entire therapeutic class. Advisory committee decisions provide a public preview of regulatory concerns and voting patterns, allowing competitors to anticipate potential label restrictions or post-market requirements. Tracking PDUFA dates establishes a concrete timeline for upcoming market entries, helping commercial teams prepare their response. Additionally, monitoring Paragraph IV filings is critical for lifecycle management. These patent challenges provide brand manufacturers with crucial advance warning of impending IP litigation and generic market entry.
Continuously reading these signals gives organizations a structural advantage. Instead of waiting for a final approval announcement, teams can predict regulatory shifts over the next 18 to 36 months. This proactive approach allows companies to adapt their clinical strategy, refine payer narratives and adjust commercial plans long before competitors can react.
Signal type 4: Deal and licensing activity signals
Deal-making, licensing agreements and merger activity do not happen spontaneously. They follow distinct patterns that serve as highly actionable competitive intelligence signals. Tracking deal timing, structure and valuation gives a clear view of how competitors evaluate the market and where they allocate their resources. For example, when a major pharma company licenses an early-stage asset in a specific indication, it validates the biological target and highlights a shift in their therapeutic focus. Monitoring this deal activity continuously helps business development teams spot which mechanisms are gaining traction and where investment capital is flowing, well before those trends appear in broader market reports.
The timing of these transactions frequently aligns with predictable events, such as Phase 2 clinical readouts or regulatory submissions. These milestones reduce risk for buyers and create clear valuation inflection points for sellers. A proactive approach to biopharma competitive intelligence involves mapping competitor deal history against upcoming clinical calendars. Rather than reacting to an acquisition announcement, BD teams can identify potential partnering opportunities 12 to 18 months before a major data readout. By cross-referencing deal patterns with pipeline data and patent filings, organizations can initiate partnership conversations at the right moment, rather than competing for assets after their valuations have already peaked.
The competitive landscape has a timing problem
Pharmaceutical competitive intelligence has historically operated in arrears. A competitor announces a Phase 3 readout. A deal closes. A regulatory submission lands on the FDA’s docket. Teams scramble to respond – updating slide decks, convening war rooms, re-running portfolio analyses. The data existed before the announcement; the organizational posture did not.
This reactive pattern is not unique to smaller organizations. Even at large pharma companies with dedicated CI functions, intelligence often arrives after targets have already been selected, generating wasted effort on crowded, undifferentiated targets or missed competitive signals (Angelopoulos, A., 2026). One large biopharmaceutical company, after integrating competitive intelligence directly into its discovery workflows, cut its target-prioritization time from four weeks to approximately five days (Angelopoulous, A., 2026). That four-week lag, in a landscape where competitors make strategic moves continuously, is not an inconvenience – it is a compounding liability.
The challenge is structural. Commercial teams track market share. Clinical teams track protocols. Regulatory teams track approvals. Rarely do these streams converge into a unified strategic view. This fragmentation creates blind spots where critical threats remain invisible until they become costly to address (Pienomial, 2025).
The anatomy of a proactive CI posture
Organizations that operate with a proactive intelligence posture share three observable characteristics (WNS, 2025; Life Science Dynamics, 2025):
Continuous monitoring, not periodic reporting. Intelligence flows between organizational functions continuously rather than through quarterly briefings or ad hoc requests. When a competitor announces a pipeline update, the response is immediate and contextualized, not deferred to the next reporting cycle. When information flows continuously across functional teams, organizations make better decisions faster, responding to competitive signals within hours rather than weeks.
Cross-functional convergence of signal streams. Pipeline data, patent filings, regulatory events and deal disclosures are read against each other, not tracked in isolation. The value of any single data point increases when placed in the context of concurrent signals from other domains.
Early-phase emphasis over late-stage surveillance. The organizations that capture the most strategic value from CI are not primarily watching Phase 3 competitors – they are watching Phase 1 registrations, preclinical filings and discovery-stage patent activity. Broader early-phase coverage, spanning more indications and geographies, enables identification of competitor programs before the competitive situation becomes costly to address (Clarivate, 2026a; Clarivate, 2026b).
An optimal competitive intelligence framework supports this architecture by integrating pipeline, patent, regulatory, deal and commercial data into a single evidence base, ensuring that cross-functional teams work from a shared, continuously updated intelligence layer rather than disconnected analytical silos.
By contrast, a reactive posture is characterized by siloed data, delayed synthesis and intelligence that informs decisions after the strategic window has closed. The data volume is the same in both cases. The organizational readiness to act on it is not (MathCo, 2025).
What the data patterns reveal
Across the tens of thousands of drug programs tracked in global pharmaceutical intelligence platforms – spanning discovery through launch, across 3,000+ diseases and all major geographies – several recurring patterns distinguish programs that succeed from those that face preventable competitive disruption (Clarivate, 2026b):
- Indication crowding accelerates fastest in oncology and immunology, where target biology is well-characterized and multiple sponsors simultaneously pursue overlapping mechanisms. Teams that map competitive positioning across an indication before committing to Phase 2 investment avoid designing studies around identical endpoints and enrolling overlapping patient populations (Angelopoulos, A., 2026).
- IP filing activity frequently precedes trial initiations in therapeutic areas with established target biology, creating a detectable pre-clinical signal window that pipeline databases alone would miss (Northern Light, 2026). Integrating patent filing data with pipeline tracking closes this gap.
- Deals that close near regulatory milestones command premium valuations, but the intelligence advantage accrues to organizations that identify deal-ready assets well before milestone events – not at the PDUFA date itself. Paragraph IV certification filings can provide up to 30 months of advance notice before any generic can launch, but only to teams monitoring FDA databases in near-real time (DrugPatentWatch, 2025).
- Protocol amendments signal competitive pressure before results are public. When a sponsor modifies trial endpoints in a crowded indication, competitors with continuous trial monitoring can read the competitive interpretation within days of the amendment posting on ClinicalTrials.gov – months before any data readout (DrugPatentWatch, 2025.
The strategic early warning system
The most productive reframe for pharmaceutical CI is not “what do we know about our competitors?” but “what do patterns in public data reveal about what our competitors are going to do?”
That reframe has practical consequences for how CI functions are structured. It prioritizes data breadth over analytical depth at the monitoring stage, because a missed signal cannot be analyzed. It prizes synthesis across domains over expertise within any single domain, because the convergence of a patent filing, a trial registration and a deal announcement means something that none of the three communicates in isolation. And it demands continuous flow rather than periodic delivery, because the competitive landscape does not pause between reporting cycles (Evaluate Pharma, 2025).
With 90% of assets entering clinical trials failing to reach the market and R&D costs continuing to rise, the cost of a missed competitive signal is not just a missed insight (Clarivate, 2025; Acta Pharmaceutica Sinica B, 2022). It is an investment allocated to a crowded indication, a partnering conversation started after the ideal window closed, or a portfolio decision made without visibility into where competitors are already committed. The signals that prevent those outcomes are not proprietary. They are sitting in plain sight.
The competitive advantage accrues to organizations that synthesize them first – and that have built the infrastructure to do so before the signals become headlines.
From signal awareness to strategic action
Translating signal awareness into strategic action requires moving beyond point-in-time competitive assessments toward a continuously refreshed intelligence architecture. For CI leaders, portfolio strategists and BD directors, this means:
- Monitoring early-phase data as aggressively as late-phase data, with particular attention to discovery and preclinical programs that precede formal clinical registrations (Clarivate, 2026a)
- Integrating patent data with pipeline tracking to detect IP filing cadence relative to trial activity, closing the window between a competitor’s R&D commitment and a team’s first awareness (Northern Light, 2026)
- Automating regulatory event tracking across the FDA, EMA and other major agencies to capture guidance publications, advisory committee decisions and approval actions that reshape the competitive environment before they become headline news (DrugPatentWatch, 2025)
- Modelling deal timing against milestone calendars to identify the optimal window for BD conversations before asset valuations are bid up by regulatory de-risking
- Bringing all signal types together in Cortellis Competitive Intelligence rather than tracking them across disconnected sources that require manual reconciliation (Clarivate, 2026b)
The organizations that lead their therapeutic areas do not have better instincts than their competitors. They have better pattern recognition – and they have built the infrastructure to act on patterns before those patterns become public knowledge.
The signals are already there. The organizations best positioned to act on them are those that have built the infrastructure to find them first.
Learn more about how Cortellis Competitive Intelligence helps pharma and biotech teams move from reactive tracking to proactive strategic foresight: Cortellis Competitive Intelligence & Analytics | Clarivate
References
Acta Pharmaceutica Sinica B (2022) Why 90% of clinical drug development fails and how to improve it? February. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC9293739/ (Accessed: 8 May 2026).
Angelopoulos, A. (2026) ‘How early-stage intelligence determines late-stage success’, Clinical Trial Vanguard, January. Available at: https://www.clinicaltrialvanguard.com/opinion/how-early-stage-intelligence-determines-late-stage-success/ (Accessed: 8 May 2026).
Clarivate (2025) Drug timeline and success rates. Available at: https://clarivate.com/life-sciences-healthcare/lp/drug-timeline-success-rates/ (Accessed: 8 May 2026).
Clarivate (2026a) Competitive intelligence. Available at: https://clarivate.com/life-sciences-healthcare/portfolio-strategy/competitive-intelligence/ (Accessed: 8 May 2026).
Clarivate (2026b) Cortellis Competitive Intelligence & Analytics. Available at: https://clarivate.com/life-sciences-healthcare/portfolio-strategy/competitive-intelligence/cortellis-competitive-intelligence-analytics/ (Accessed: 8 May 2026).
DrugPatentWatch (2025) Transforming biopharma intelligence: Moving from traditional analysts to direct raw data platforms. Available at: https://www.drugpatentwatch.com/blog/transforming-biopharma-intelligence-moving-from-traditional-analysts-to-direct-raw-data-platforms/ (Accessed: 8 May 2026).
Evaluate Pharma (2025) Enhancing competitive intelligence in biopharma. Available at: https://www.evaluate.com/blog/enhancing-competitive-intelligence-in-biopharma/ (Accessed: 8 May 2026).
GSK (2025) GSK and Hengrui Pharma enter agreements to develop up to 12 medicines. Press release, 28 July. Available at: https://www.gsk.com/en-gb/media/press-releases/gsk-and-hengrui-pharma-enter-agreements/ (Accessed: 8 May 2026).
Life Science Dynamics (2025) What’s driving competitive intelligence in pharma today? Available at: https://www.lifesciencedynamics.com/press/articles/whats-driving-competitive-intelligence-in-pharma-today/ (Accessed: 8 May 2026).
MathCo (2025) Pharma competitive intelligence: Signals that matter. Available at: https://mathco.com/blog/pharma-competitive-intelligence-signals-that-matter/ (Accessed: 8 May 2026).
Northern Light (2026) What is life sciences intelligence – and why early signals matter more than ever. March. Available at: https://www.northernlight.com/blog/what-is-life-sciences-intelligence–and-why-early-signals-matter-more-than-ever (Accessed: 8 May 2026).
Pienomial (2025) Why competitive intelligence is reshaping clinical strategy. Available at: https://www.pienomial.com/blog/why-competitive-intelligence-is-reshaping-clinical-strategy-in-pharma (Accessed: 8 May 2026).
WNS (2025) Competitive intelligence in pharma: Staying ahead in a market that won’t wait. Available at: https://www.wns.com/perspectives/blogs/competitive-intelligence-in-pharma-staying-ahead-in-a-market-that-wont-wait (Accessed: 8 May 2026).
Related insights
The latest news, technologies, and resources from our team.
